Ipsen S.A.

Ipsen is a global biopharmaceutical company headquartered in Paris, France, dedicated to innovation and specialty care. Its core mission is to prolong and improve patients' lives and health outcomes through innovative pharmaceutical solutions, aiming to make a positive impact on society.

The company focuses its research and development efforts and product portfolio across three key therapeutic areas: oncology, rare diseases, and neuroscience. Key products include Dysport® for neuroscience indications, Somatuline® and Cabometyx® for oncology, and Sohonos™ and Iqirvo® for rare diseases. Ipsen strategically divested its Consumer HealthCare division in July 2022 to sharpen its focus exclusively on high-value specialty therapeutics.

Led by CEO David Loew, appointed in July 2020, Ipsen maintains a strong market position as a global leader in specialty pharmaceuticals. The company reported strong sales growth in the first quarter of 2026 and continues to expand its pipeline through internal innovation and strategic partnerships. Recent developments include the European Union approval of Ojemda® for pediatric low-grade glioma in April 2026 and the appointment of Michelle C. Werner as EVP, President of North America in March 2026. Ipsen was ranked 52nd among the top pharma companies by revenue in 2026.